TIDMAGL
Angle PLC
13 February 2017
For immediate release 13 February 2017
ANGLE plc ("the Company")
PARSORTIX SELECTED FOR EUROPEAN CANCER-ID PROGRAMME
ANGLE plc (AIM: AGL OTCQX: ANPCY), the specialist medtech
company, is pleased to announce that it has been formally selected
for CANCER-ID, the European consortium to validate blood-based
biomarkers for cancer.
CANCER-ID is a European consortium funded by the Innovative
Medicines Initiative (IMI), with a total budget exceeding EUR14
million, bringing together 38 partners from 13 countries, and aimed
at the establishment of standard protocols for and clinical
validation of blood-based biomarkers to enable liquid biopsies to
become routine clinical practice.
University Medical Center Hamburg-Eppendorf, University of
Twente, Bayer AG and Menarini Silicon Biosystems coordinate the
consortium, bringing together experts from academic and clinical
research to the life sciences industry to provide a unique setting
to establish the clinical utility of liquid biopsies.
ANGLE's participation in the consortium involves a contribution
to the programme in the form of a number of Parsortix instruments
and associated consumables for evaluation. The evaluation will
assess the suitability of the Parsortix system being adopted as a
standard circulating tumour cell (CTC) harvesting system to be used
alongside a variety of different molecular analysis techniques in
standard operating protocols. Running until 2020, an initial
evaluation phase will be followed by a clinical phase to establish
the use of liquid biopsies in treating lung and breast cancer. This
is intended to provide clinical evidence to support the adoption of
liquid biopsy in routine cancer care.
The academic leads of the CANCER-ID consortium are Prof. Klaus
Pantel, Head of the Department of Tumor Biology at the University
Medical Center Hamburg-Eppendorf, Germany, and Prof. Leon
Terstappen, Head of the Department of Medical Cell Biophysics at
the University of Twente, The Netherlands. Both are leaders in the
field of liquid biopsy and have an impressive track record in both
basic research and applied science including device development.
The lead companies of the CANCER-ID consortium are Bayer AG and
Menarini Silicon Biosystems.
ANGLE Founder and Chief Executive, Andrew Newland, said:
"The CANCER-ID project is focusing on developing and setting
standard protocols for the use of CTC liquid biopsies and the
clinical validation of blood-based biomarkers. We are delighted to
be part of this programme as it offers the Parsortix system the
potential to be specified as a standard CTC harvesting system for
clinical use in patients with lung cancer and breast cancer in
Europe, with the opportunity for collaboration with multiple
downstream analysis companies."
Professor Klaus Pantel, the University Medical Center
Hamburg-Eppendorf, commented:
"Blood-based analysis of tumor derived cells and nucleic acids
offer a novel concept of liquid biopsies to provide real-time
information relevant to cancer diagnosis and therapy. The CANCER-ID
project fills the substantial gap between basic research focused on
novel methods for the detection and characterisation of circulating
tumor cells and nucleic acids, and the development of robust
validated assays required to bring the liquid biopsy concept into
the clinic."
Dr Thomas Schlange, Biomarker Research, Bayer AG Drug Discovery,
added:
"CANCER-ID is an excellent example of a project in which a
public-private partnership enables a collaborative research
approach to come up with novel concepts in modern cancer therapy.
The consortium brings together a large experienced team of
biomarker experts across Europe that extends far beyond the scope
of traditional 'one-on-one' industry-academia collaborations."
ANGLE plc 01483 685830
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Cenkos Securities
Stephen Keys (Nominated adviser),
Steve Cox
Russell Kerr (Sales) 020 7397 8900
WG Partners
David Wilson
Claes Spång 020 3705 9330
FTI Consulting
Simon Conway, Mo Noonan,
Stephanie Cuthbert 020 3727 1000
Kimberly Ha (US) 001 212 850 5612
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a specialist medtech company commercialising a
disruptive platform technology that can capture cells circulating
in blood, such as cancer cells, even when they are as rare in
number as one cell in one billion blood cells, and harvest the
cells for analysis.
ANGLE's cell separation technology is called the Parsortix(TM)
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in Europe, the United States, Canada, China, Japan
and Australia and three extensive families of patents are being
progressed worldwide. The system is based on a microfluidic device
that captures live cells based on a combination of their size and
compressibility. Parsortix has a CE Mark for Europe and FDA
authorisation is in process for the United States.
ANGLE has established formal collaborations with world-class
cancer centres. These Key Opinion Leaders are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. Details are available here
http://www.angleplc.com/the-company/collaborators/
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is
set to drive a multi-billion dollar clinical market. The Parsortix
system is designed to be compatible with existing major medtech
analytical platforms and to act as a companion diagnostic for major
pharma in helping to identify patients that will benefit from a
particular drug and then monitoring the drug's effectiveness.
As well as cancer, the Parsortix technology has the potential
for deployment with several other important cell types in the
future.
ANGLE stock trades on the AIM market of the London Stock
Exchange under the ticker symbol AGL and in New York on the OTC-QX
under the ticker symbol ANPCY. For further information please
visit: www.angleplc.com
About the Innovative Medicines Initiative (IMI) www.imi.europa.eu
The Innovative Medicines Initiative (IMI) is working to improve
health by speeding up the development of, and patient access to,
innovative medicines, particularly in areas where there is an unmet
medical or social need. It does this by facilitating collaboration
between the key players involved in healthcare research, including
universities, the pharmaceutical and other industries, small and
medium-sized enterprises (SMEs), patient organizations and
medicines regulators.
IMI is a partnership between the European Union and the European
pharmaceutical industry, represented by the European Federation of
Pharmaceutical Industries and Associations (EFPIA). Through the IMI
2 programme, IMI has a budget of EUR3.3 billion for the period
2014-2024. Half of this comes from the EU's research and innovation
programme, Horizon 2020. The other half comes from large companies,
mostly from the pharmaceutical sector; these do not receive any EU
funding, but contribute to the projects 'in kind', for example by
donating their researchers' time or providing access to research
facilities or resources.
This project has received funding from the Innovative Medicines
Initiative 2 Joint Undertaking under grant agreement No 115749.
This Joint Undertaking receives support from the European Union's
Horizon 2020 research and innovation programme and EFPIA.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRATTMLTMBIBBMR
(END) Dow Jones Newswires
February 13, 2017 02:00 ET (07:00 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024